Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4KANOSKI, Scott E; FORTIN, Samantha M; ARNOLD, Myrtha et al.Endocrinology (Philadelphia). 2011, Vol 152, Num 8, pp 3103-3112, issn 0013-7227, 10 p.Article

Le liraglutideGERSON, Michel.Médecine (Montrouge). 2010, Vol 6, Num 7, pp 302-305, issn 1777-2044, 4 p.Article

Liraglutide in combination with acitretin for severe recalcitrant psoriasisREID, C. T; TOBIN, A. M; AHERN, T et al.British journal of dermatology (1951). 2013, Vol 169, Num 1, pp 230-231, issn 0007-0963, 2 p.Article

Tritium labelling of the GLP-1 analogue liraglutideLARSEN, Uffe S; HANSEN, Heidi B; DAHL, Anne-Mette et al.Journal of labelled compounds & radiopharmaceuticals. 2007, Vol 50, Num 5-6, pp 549-550, issn 0362-4803, 2 p.Conference Paper

Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical ConsiderationsCARRIS, Nicholas W; TAYLOR, James R; GUMS, John G et al.Drugs (Basel). 2014, Vol 74, Num 18, pp 2141-2152, issn 0012-6667, 12 p.Article

Circulating SfrpS Is a Signature of Obesity-Related Metabolic Disorders and Is Regulated by Glucose and Liraglutide in HumansWENJING HU; LING LI; MENGLIU YANG et al.The Journal of clinical endocrinology and metabolism. 2013, Vol 98, Num 1, pp 290-298, issn 0021-972X, 9 p.Article

GLP-1 Receptor Agonists: Effects on Cardiovascular Risk ReductionLORBER, Daniel.Cardiovascular therapeutics (Print). 2013, Vol 31, Num 4, pp 238-249, issn 1755-5914, 12 p.Article

Glucagon-Like Peptide-1 Receptor Agonist Administration Suppresses Both Water and Saline Intake in RatsMCKAY, N. J; DANIELS, D.Journal of neuroendocrinology. 2013, Vol 25, Num 10, pp 929-938, issn 0953-8194, 10 p.Article

Retrospective Real-World Adherence in Patients With Type 2 Diabetes Initiating Once-Daily Liraglutide 1.8 mg or Twice-Daily Exenatide 10 μgMALMENÄS, Maria; BOUCHARD, Jonathan R; LANGER, Jakob et al.Clinical therapeutics. 2013, Vol 35, Num 6, pp 795-807, issn 0149-2918, 13 p.Article

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD programARMSTRONG, M. J; HOULIHAN, D. D; ROWE, I. A et al.Alimentary pharmacology & therapeutics. 2013, Vol 37, Num 2, pp 234-242, issn 0269-2813, 9 p.Article

Analogues du GLP-1 et éducation du patient diabétique de type 2 = Educational prescription and patient education checklist for GLP-1 agonists in type 2 diabetesLAGRANGE, F.Le Pharmacien hospitalier. 2011, Vol 46, Num 1, pp 56-65, issn 0768-9179, 10 p.Article

Administration of an acylated GLP-I and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesityGAULT, Victor A; KERR, Barry D; HARRIOTT, Patrick et al.Clinical science (1979). 2011, Vol 121, Num 3-4, pp 107-117, issn 0143-5221, 11 p.Article

Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for TreatmentNEUMILLER, Joshua J.Clinical therapeutics. 2011, Vol 33, Num 5, pp 528-576, issn 0149-2918, 49 p.Article

Place in Therapy for Liraglutide and Saxagliptin for Type 2 DiabetesSHAWN MCFARLAND, M; BROCK, Meghan; RYALS, Casey et al.Southern medical journal (Birmingham, Ala. Print). 2011, Vol 104, Num 6, pp 426-439, issn 0038-4348, 14 p.Article

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trialPRATLEY, Richard E; NAUCK, Michael; BAILEY, Timothy et al.Lancet (British edition). 2010, Vol 375, Num 9724, pp 1447-1456, issn 0140-6736, 10 p.Article

Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesusVEDTOFTE, Louise; BODVARSDOTTIR, Thora B; GOTFREDSEN, Carsten F et al.Regulatory peptides. 2010, Vol 160, Num 1-3, pp 106-114, issn 0167-0115, 9 p.Article

Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral EndopeptidaseMALM-ERJEFÄLT, Monika; BJORNSDOTTIR, Inga; VANGGAARD, Jan et al.Drug metabolism and disposition. 2010, Vol 38, Num 11, pp 1944-1953, issn 0090-9556, 10 p.Article

A Review of Efficacy and Safety Data Regarding the Use of Liraglutide, a Once-Daily Human Glucagon-Like Peptide 1 Analogue, in the Treatment of Type 2 Diabetes MellitusMONTANYA, Eduard; SESTI, Giorgio.Clinical therapeutics. 2009, Vol 31, Num 11, pp 2472-2488, issn 0149-2918, 17 p.Article

Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes MellitusDRAB, Scott R.Pharmacotherapy. 2009, Vol 29, Num 12, issn 0277-0008, 43S-54S, 2Article

The Intersection of Safety and Adherence: New Incretin-Based Therapies in Patients with Type 2 Diabetes MellitusZAROWITZ, Barbara J; CONNER, Christopher.Pharmacotherapy. 2009, Vol 29, Num 12, issn 0277-0008, 55S-67S, 2Article

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetesHARDER, Helle; NIELSEN, Lens; THI, Tu D. T et al.Diabetes care. 2004, Vol 27, Num 8, pp 1915-1921, issn 0149-5992, 7 p.Article

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adultsLEAN, M. E. J; CARRARO, R; FINER, N et al.International journal of obesity. 2014, Vol 38, Num 5, pp 689-697, issn 0307-0565, 9 p.Article

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetesROSS, Stuart A; BALLANTINE, Jane.Current medical research and opinion. 2013, Vol 29, Num 12, pp 1617-1626, issn 0300-7995, 10 p.Article

The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodentsEGECIOGLU, Emil; STEENSLAND, Pia; FREDRIKSSON, Ida et al.Psychoneuroendocrinology. 2013, Vol 38, Num 8, pp 1259-1270, issn 0306-4530, 12 p.Article

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetesCORNELL, S.Journal of clinical pharmacy and therapeutics (Print). 2012, Vol 37, Num 5, pp 510-524, issn 0269-4727, 15 p.Article